单独内路明胶微支架植入与单独小梁切除术的疗效、安全性及失败危险因素比较
这项国际多中心回顾性干预队列研究比较了无既往内眼手术的眼部接受单独内路明胶微支架联合丝裂霉素C(MMC)与小梁切除术联合MMC的疗效、安全性及失败危险因素,共纳入354眼(微支架185眼,小梁切除169眼)。调整后失败风险比在完全成功和条件成功中均无显著差异,白色人种与失败风险降低相关,糖尿病与失败风险升高相关,两组安全性和再手术率无显著差异。
要点
- 微支架组与小梁切除组调整后完全成功失败HR为1.2(95%CI 0.7-2.0),条件成功失败HR为1.3(95%CI 0.6-2.8),均无显著差异。
- 白色人种与失败风险降低相关(调整后HR 0.49,95%CI 0.25-0.96),糖尿病与失败风险升高相关(调整后HR 4.21,95%CI 2.10-8.45)。
- 两组再手术率分别为10%和5%(P=0.11),并发症多数为一过性。
核心结论
- 单独内路明胶微支架联合MMC与单独小梁切除术联合MMC在失败风险和安全特征上未检测到差异。
研究设计与样本
- 国际多中心回顾性干预队列研究,纳入2011年1月1日至2015年7月31日在加拿大多伦多、德国法兰克福、奥地利萨尔茨堡和比利时鲁汶4个学术眼科中心连续接受手术的无既往内眼手术的未控制青光眼眼。
- 共纳入293例患者的354眼,其中微支架组185眼,小梁切除术组169眼。
主要发现
- 微支架组相对小梁切除术组的调整后失败HR为完全成功1.2(95%CI 0.7-2.0),条件成功1.3(95%CI 0.6-2.8),其他结局相似。
- 完全成功达到25%失败的时间为微支架组11.2个月(95%CI 6.9-16.1)vs 小梁切除组10.6个月(95%CI 6.8-16.2);条件成功为30.3个月(95%CI 19.0-∞)vs 33.3个月(95%CI 25.7-46.2)。
- 白色人种与失败风险降低相关(调整后HR 0.49,95%CI 0.25-0.96),糖尿病与失败风险升高相关(调整后HR 4.21,95%CI 2.10-8.45)。
- 微支架组和小梁切除组分别有117次和165次不同干预,分别有43%和31%接受针刺,50%的小梁切除眼接受激光缝线松解。
- 微支架组和小梁切除组分别有22次和30次不同并发症,多数为一过性;再手术率分别为10%和5%(P=0.11)。
关键数值与推荐
- 失败定义:术后至少1个月,尽管进行了包括针刺在内的诊室干预,仍出现连续2次眼压<6 mmHg伴视力丧失或>17 mmHg且未使用青光眼药物(完全成功)。
- 次要结局包括眼压阈值6-14 mmHg和6-21 mmHg及相同阈值允许用药(条件成功)、干预、并发症和再手术。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the efficacy, safety, and risk factors for failure of standalone ab interno gelatin microstent implantation with mitomycin C (MMC) versus trabeculectomy with MMC. DESIGN: International, multicenter, retrospective interventional cohort study. PARTICIPANTS: Three hundred fifty-four eyes of 293 patients (185 microstent and 169 trabeculectomy) with no prior incisional surgery. METHODS: Consecutive eyes with uncontrolled glaucoma underwent microstent or trabeculectomy surgery from January 1, 2011 through July 31, 2015 at 4 academic ophthalmology centers: Toronto, Canada; Frankfurt, Germany; Salzburg, Austria; and Leuven, Belgium. MAIN OUTCOME MEASURES: Primary outcome measure was hazard ratio (HR) of failure, with failure defined as 2 consecutive intraocular pressure (IOP) readings of <6 mmHg with vision loss or >17 mmHg without glaucoma medications (complete success) at least 1 month after surgery despite in-clinic interventions (including needling). Secondary outcome measures included IOP thresholds of 6 to 14 mmHg and 6 to 21 mmHg and same thresholds allowing for medications (qualified success), interventions, complications, and reoperations. RESULTS: Baseline characteristics were similar, except more men (56% vs. 43%), younger patients (average, by 3 years), better preoperative visual acuity (22% vs. 32% with 0.4 logarithm of the minimum angle of resolution vision or worse), and more trabeculoplasty (52% vs. 30%) among microstent eyes. The adjusted HR of failure of the microstent relative to trabeculectomy was 1.2 (95% confidence interval [CI], 0.7-2.0) for complete success and 1.3 (95% CI, 0.6-2.8) for qualified success, and similar for other outcomes. Time to 25% failure was 11.2 months (95% CI, 6.9-16.1 months) and 10.6 months (95% CI, 6.8-16.2 months) for complete success and 30.3 months (95% CI, 19.0-∞ months) and 33.3 months (95% CI, 25.7-46.2 months) for qualified success. Overall, white ethnicity was associated with decreased risk of failure (adjusted HR, 0.49; 95% CI, 0.25-0.96), and diabetes was associated with increased risk of failure (adjusted HR, 4.21; 95% CI, 2.10-8.45). There were 117 and 165 distinct interventions: 43% and 31% underwent needling, respectively, and 50% of trabeculectomy eyes underwent laser suture lysis. There were 22 and 30 distinct complications, although most were transient. Ten percent and 5% underwent reoperation (P = 0.11). CONCLUSIONS: There was no detectable difference in risk of failure and safety profiles between standalone ab interno microstent with MMC and trabeculectomy with MMC.
引用
- Schlenker MB, Gulamhusein H, Conrad-Hengerer I, et al. Efficacy, Safety, and Risk Factors for Failure of Standalone Ab Interno Gelatin Microstent Implantation versus Standalone Trabeculectomy. Ophthalmology. 2017. PMID: 28601250. doi:10.1016/j.ophtha.2017.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。